Prop 65 NRT litigation
This article was originally published in The Tan Sheet
Executive Summary
Plaintiff Paul Dowhal "is mistaken" in asserting that FDA has only rejected one Prop 65 warning for NRT products, according to a reply brief filed in California Supreme Court June 16. "FDA has prohibited use of any articulation of the message that [Prop 65] requires...because it has determined that the substance of this message conflicts with the FD&C Act's prohibition on misbranding and thwarts the objective of avoiding overwarning," the brief maintains. Filed on behalf of 10 NRT manufacturers, marketers and retailers, the filing also takes issue with Dowhal's contention the firms rely on informal FDA correspondence to support their opposition to a Prop 65 warning (1"The Tan Sheet" April 28, 2003, p. 9). Dowhal "ignores the fact that this correspondence includes five NDA approval letters," the reply brief notes...
You may also be interested in...
NRT Firms’ Deference To “Informal” FDA Letters In Prop 65 Case Improper
NRT firms' reliance on "unpublished, ad hoc" FDA statements to support their contention that a Proposition 65 warning on OTC smoking cessation products conflicts with federal law is improper, according to a brief filed in California Supreme Court April 15
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.
Pair Of Deaths Linked To Recalled Vyaire Medical Respiratory Devices
The US FDA has labelled a recall of more than 6 million Airlife respiratory support devices class I. The recall covers devices manufactured in 2017 or earlier that can fail to provide adequate ventilation.